Review ArticleReview Article
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease
Vincent Pons and Serge Rivest
Robert Dantzer, ASSOCIATE EDITOR, Neuroscience Laboratory, CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Québec City, QC G1V 4G2, Canada
Pharmacological Reviews January 2022, 74 (1) 1-17; DOI: https://doi.org/10.1124/pharmrev.121.000400
Vincent Pons
Neuroscience Laboratory, CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Québec City, QC G1V 4G2, Canada
Serge Rivest
Neuroscience Laboratory, CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Québec City, QC G1V 4G2, Canada
Robert Dantzer
Neuroscience Laboratory, CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Québec City, QC G1V 4G2, Canada
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
Innate Immunity and Alzheimer's Disease
Vincent Pons and Serge Rivest
Pharmacological Reviews January 1, 2022, 74 (1) 1-17; DOI: https://doi.org/10.1124/pharmrev.121.000400
Jump to section
- Article
- Abstract
- I. Alzheimer Disease
- II. Cerebral Amyloid Angiopathy
- III. Innate Immune System
- IV. Development of Monocytic Lineage
- V. The Role of Monocytes
- VI. Microglia Development and Role
- VII. Modulation of the Innate Immune System in AD
- VIII. Targeting the mCSF/CSFS1R Axis
- IX. Triggering Patrolling Monocytes to Clear Vascular Aβ
- X. Targeting TLR4
- XI. Final Remarks
- Acknowledgments
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement